SARTORIUS AG : Q2 2018 group results in line; full-year outlook raised driven by BPS
>Group Q2 2018 results in line; BPS segment beats, LPS misses - Sartorius polished its Q2 2018 results today (24 July). i) Sales were up 9.0% reported to € 393.5m in line with our estimate of € 394m (Q2 2017: € 359.4m). ii) Adjusted EBITDA increased c.14.3% yoy to € 100.9m (Q2 17: € 88.3m) leading to an adj. EBITDA margin of 25.6%. Reported adj. EBITDA and the EBITDA margin were in line with our expectations (€ 100m/ 25.4%). Group order intake for the group increased ...Sartorius is a holding company, which is engaged as an international laboratory and process technology provider for the biotech, pharmaceutical and food industries. Co. has three segments: the Bioprocess Solutions, which provides solutions for the core process steps in biopharmaceutical production, focusing on the areas of activity of filtration, fluid management, fermentation, and purification; the Lab Products & Services, which serves both research and quality assurance laboratories across several different industries; and the Industrial Weighing, which concentrates on weighing and control applications in the manufacturing processes of the food, chemical and pharmaceutical sectors.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.